Summary
You may be eligible for this study if you are over the age of 18, are referred for single-fraction stereotactic ablative radiotherapy (SF-SABR) and have early stage non-small cell lung cancer.
Participating in this research involves undergoing your SABR treatment according to a different timeframe to what would normally happen. It also involves completing a short, anonymised survey after your treatment to provide feedback on your experience of the treatment.
You visit the hospital for the simulation scan which the treatment team uses to plan and design your treatment. This happens whether or not you are participating in the study. However, if you are not on the study, you go home after this scan and the team works on the plan in the background. You are called back for treatment approximately two weeks later and undergo treatment as an outpatient.
If you choose to participate in the study, your treatment will happen within the same visit, customised to on eof two options based on your travel requirements:
- If most convenient to attend for a morning planning CT scan, treatment will be delivered in the afternoon. There will be a gap of roughly 4-6 hours between scan and treatment. You are free to leave the hospital during this time. Total time in the hospital may be anywhere from approximately 2-8 hours on that day.
- If most convenient to attend for an afternoon planning CT scan, treatment will be delivered the next morning.
You will also meet with one of our nurse specialists who will discuss arrangements for your follow up after the treatment, and give you printed information about this and the experience survey. You will be provided with a $50 voucher for the 'Super Eight' cafe on the ground floor at Peter Mac to cover the cost of beverages and/or meals on the day of your attendance. A follow-up consultation with your radiation oncologist will also be arranged approximately two weeks later. This can be arranged as a 'virtual' telehealth appointment if you prefer.
It is hoped this research will contribute to the development of streamlined, patient-centred treatment pathways and improve access to timely, high-quality SABR, potentially enhancing health outcomes for people with early-stage NSCLC.